Authentic independent research on Pharma & Biotech pipeline assets

Sequela Research delivers high-impact biotech analyses rooted in deep scientific expertise and scar-tissues shaped by prior success and failures in making the calls. Sometimes, we make contrarian calls: we believed TIGIT will fail before this became the reality across the entire class. We illuminate complex and ambiguous early clinical signals with clarity, offering unique perspectives and benchmarking that generate informed understanding about the probabilities of success (PoS) of clinical pipeline programs. We are independent and are not sponsored by any pharmaceutical or biotechnology companies, investment banks or institutional investors. We limit our analyses to inform what is truly the informative metrics for pipeline biotech assets, such as the PoS and benchmarking of clinical programs. We do not offer investment advice, and our analyses are for informational purposes only.